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Abstract—It has been reported that hepatitis C virus (HCV) may cause oxidative stress in infected cells. Patients with
chronic hepatitis C exhibit an increased production of tumor necrosis factor-a (TNFa), a cytokine that can produce
oxidative stress by stimulating the generation of reactive oxygen species (ROS). Cell defense against ROS includes
overexpression of Mn-superoxide dismutase (SOD), an inducible mitochondrial enzyme. To investigate cell defense
against oxidative stress in HCV infection, we analyzed Mn-SOD mRNA in liver and in peripheral blood mononuclear
cells (PBMC) from patients with chronic hepatitis C. Mn-SOD expression in PBMC was significantly increased in
patients with HCV infection. Patients with sustained virological and biochemical response after therapy showed
significantly lower Mn-SOD than patients with positive viremia. By contrast, Mn-SOD expression was not enhanced in
the liver of patients with chronic hepatitis C. The values of Mn-SOD mRNA did not correlate with TNFa mRNA
expression, viral load, or liver disease activity. Our results indicate that in HCV infection an induction of Mn-SOD was
present in PBMC but absent in the liver, suggesting that this organ could be less protected against oxidative damage.
Oxidative stress could participate in the pathogenesis of HCV infection. © 1998 Elsevier Science Inc.
Keywords—Superoxide-dismutase, PCR, Oxidative stress, TNFa, Hepatitis C virus genotypes, Viral load, Free
radicals
INTRODUCTION
Hepatitis C virus (HCV) is a hepatotropic and lympho-
tropic agent1 with a strong tendency to establish chronic
infections. The pathogenesis of HCV infection is not
well understood. It has been suggested that HCV may
cause oxidative stress in infected cells. Several lines of
evidence support this contention, including the existence
of an activated glutathione turnover, the presence of
increased levels of lipid peroxidation products and aug-
mented iron stores in the liver,2–4 and the finding of
diminished reduced glutathione values in peripheral
blood mononuclear cells (PBMC) and erythrocytes.5,6
Moreover, it has been shown that patients with chronic
hepatitis C exhibit an increased production of tumor
necrosis factor-a (TNFa),7 a cytokine that can produce
oxidative stress by stimulating the generation of reactive
oxygen species (ROS) such as superoxide ion (O2z2) and
hydrogen peroxide (H2O2).8
Reactive oxygen metabolites are mainly produced in
mitochondria during electron transport9,10 but also, to a
lesser extent, in endoplasmic reticulum, peroxisomes,
and nuclear and plasma membrane.10 ROS can damage
cells by causing lipid peroxidation and oxidative damage
of DNA and proteins11 and by depleting ATP stores.12 In
the presence of metals (such as Fe31), O2z2 can react
with H2O2 to generate a hydroxyl radical that is even
more reactive and cytotoxic than O2z2 or H2O2.10
Cells are protected against oxidative insults by natural
antioxidant products, notably glutathione, and by diverse
antioxidant enzymes such as superoxide dismutase
(SOD), catalase, and glutathione peroxidase. SOD cata-
lyzes the dismutation of O2z2 to H2O2 and O2, whereas
glutathione peroxidase and catalase scavenge H2O2.13,14
By rapidly eliminating O2z2, SOD reduces the produc-
tion of hydroxyl radical, thus attenuating oxidative dam-
age of cellular constituents.
Eukaryotic cells have an extracellular SOD (EC-
SOD) and two forms of intracellular SOD: one is found
in the mitochondrial matrix, the manganese SOD (Mn-
SOD), and another is predominantly present in citosol,
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the copper-zinc SOD (CuZn-SOD).15,16 Synthesis of
CuZn-SOD is constitutive, whereas Mn-SOD is induc-
ible. Mn-SOD expression is enhanced by TNFa and
other inflammatory mediators that cause intracellular re-
lease of oxidant compounds.17,18 Also, other agents and
treatments that generate oxidative insult such as x-ray
irradiation and hyperoxia19,20 can induce directly or in-
directly the synthesis of Mn-SOD. These observations
together with the strategic localization of Mn-SOD in
mitochondria, a main site of ROS production, suggest
that Mn-SOD is important in the protection against ox-
idative stress.
Because in chronic HCV infection there is an in-
creased production of TNFa and there are data indicating
the presence of oxidative stress, in the present work we
have analyzed the levels of Mn-SOD mRNA in PBMC
and in the liver in this condition.
MATERIALS AND METHODS
Patients
We have studied Mn-SOD and TNFa mRNA levels
in 56 PBMC samples from 44 patients with chronic
hepatitis C; 36 showed positive serum HCV-RNA (28
male, 8 female, age range from 22–71), and 20 corre-
sponded to patients with sustained complete response
to interferon (IFN) treatment (persistent normal serum
transaminases and negative HCV-RNA in serum for at
least 6 months after completion of 1 year IFN treat-
ment) (13 male, 7 female, age range from 17–51). In
12 patients, who showed sustained response to the
therapy, the study was performed on two occasions—
before and after completion IFN therapy. Twenty
healthy subjects (7 male, 13 female, age range from
25–38) were studied as controls.
A fragment of the liver biopsy obtained for diagnostic
purposes was used for analysis of transcriptional expres-
sion of Mn-SOD and TNFa in 16 patients with chronic
hepatitis C (9 males and 7 females; age range 26–64). In
addition, in 12 controls (7 males and 5 females; age
range 41–66 years) liver samples were taken at laparot-
omy for diagnostic purposes (in 5 cases because of
gallstones and in 7 because of pancreatic cancer or can-
cer of the rectum without apparent liver metastasis).
Serum levels of Mn-SOD protein were determined in
19 healthy controls, 19 serum HCV-RNA–positive and
18 serum HCV-RNA–negative patients included in the
study.
Diagnosis of chronic hepatitis C was based on eleva-
tion of serum transaminases for more than 6 months,
positivity for anti-HCV antibodies (ELISA second gen-
eration, Ortho Diagnostic Systems, Raritan, NJ), pres-
ence of HCV-RNA (reverse transcription-PCR) in serum
and histological evidence of chronic hepatitis. Causes of
chronic liver disease other than HCV were excluded: in
particular, alcoholic patients were not included in this
study.
Preparation of PBMC, liver specimens, and serum
samples
For isolation of PBMC, fresh blood diluted with 1
volume of 0.9% NaCl was overlaid on Lymphopred
(Nycomed Pharma AS, Oslo, Norway) with a density of
1.077 g/ml and centrifuged 600 3 g for 30 min. The
mononuclear cell layer was harvested at the interphase
and washed twice in 0.9% NaCl. PBMC were lysed in 4
mol/l guanidinium thiocyanate and stored at 280°C until
extraction of total RNA, which was performed according
to the method of Chomczynski and Sacchi.21 To obtain
serum samples, venous blood was taken into sterile vac-
uum blood collection tubes and then centrifuged. Serum
was stored at 270°C until used. Liver specimens were
obtained with Tru-Cut biopsy needles (Baxter, Deerfield,
IL). One-third of the biopsy was immediately frozen in
liquid nitrogen and stored at 280°C until the extraction
of RNA, and the remaining was used for histological
study.
Analysis of mRNA levels of Mn-SOD and TNFA in
PBMC and in the liver
Estimation of TNFa mRNA levels was carried out
using a quantitative reverse transcription-PCR proce-
dure as previously described.7 To determine Mn-SOD
mRNA levels we used a similar procedure. Either
PBMC or liver total RNA (1.25 or 0.75 mg, respec-
tively) was reverse-transcribed (60 min at 37°C) with
200 U of M-MuLV reverse transcriptase (BRL, Gaith-
ersburg, MD) in 25 ml volume of 53 RT buffer (0.25
mol/l Tris–HCl pH 8.3, 0.375 mol/l KCl, 15 mmol/l
MgCl2), supplemented with 5 mmol/l DTT, 0.4
mmol/l deoxynucleoside triphosphate, ribonuclease
inhibitor (30 U), and random hexamers (250 ng) (Boe-
hringer–Mannheim, Mannheim, Germany). After heat-
ing (95°C, 5 min) and quick chilling on ice, an aliquot
of 10 ml (0.5 or 0.3 mg for PBMC and liver, respec-
tively) of the cDNA pool was used for PCR amplifi-
cation of Mn-SOD in 50 ml of 103 PCR buffer (100
mmol/l Tris–HCl pH 9.0, 500 mmol/l KCl, and 1%
Triton X-100) containing 70 mCi/ml of (a-32P)-deoxy-
citidine triphosphate (Amersham, Buckinghamshire,
UK), upstream and downstream primers (40 ng each),
1.5 mmol/l MgCl2 and 2 U of Taq DNA polymerase
(Promega Corporation, MD). Blank reactions with no
RNA were performed in all experiments. As internal
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control for each sample, PCR amplification of a frag-
ment of b-actin cDNA (using 10 ml aliquot of the
cDNA pool) was performed as previously described.7
Mn-SOD cDNA fragments were amplified by 24 or 23
cycles (PBMC or liver, respectively) (94, 60, and
72°C, 1 min each step), and b-actin was amplified by
20 cycles (94, 55, and 72°C, 1 min each step), a
protocol that avoided interference of the plateau ef-
fect. Oligonucleotides (59-39) d(TGCACCACAG-
CAAGCACCAC) and d(AAACCAAGCCAAC-
CCCAACC) were the upstream and downstream prim-
ers, respectively, used for amplification of 310 bp
fragment from human Mn-SOD cDNA.22 After PCR
amplifications, 20 ml aliquots of the PCR reactions
were electrophoresed in 2% agarose gel and bands
were visualized using ethidium bromide. Agarose
fragments of the same size containing these bands
were excised and radioactivities were determined. Ob-
tained values were corrected for background radioac-
tivity from blank reactions with no RNA. Finally,
values corresponding to Mn-SOD mRNA were nor-
malized to those of b-actin mRNA, and results were
expressed as cpm ratio of Mn-SOD to b-actin. Mn-
SOD mRNA values were normalized to those of b-ac-
tin mRNA because we had previously demonstrated
that b-actin mRNA was constantly expressed in pa-
tients with chronic hepatitis C with or without IFN
treatment.7
Validation experiments of PCR assays using known
quantities of total RNA (from 0 to 1 mg) were carried
out. As shown in Fig. 1, resultant cpm values corre-
sponding to the amount of Mn-SOD or b-actin mRNA
used (0.5 and 0.3 g in PBMC and liver, respectively)
were in the linear part of the curve. To analyze whether
changes of Mn-SOD mRNA levels relative to those of
b-actin resulted in changes in the ratio of Mn-SOD PCR
product cpm/b-actin PCR product cpm, we performed a
reverse transcription-PCR with 0.2 or 0.5 mg of total
PBMC RNA from a healthy control (for Mn-SOD or
b-actin, respectively) and serial dilutions of known quan-
tities of Mn-SOD riboprobe (from 40 to 0.16 pg) were
added. Mn-SOD riboprobe was obtained by run-off tran-
scription of a plasmid that contained a 310 bp insert from
the human Mn-SOD cDNA. As shown in Fig. 2, with
increasing amounts of Mn-SOD mRNA used in the re-
action, we obtained a progressive increase of the Mn-
SOD/b-actin ratio (the increase was linear up to 1.25 pg
of the Mn-SOD riboprobe).
The coefficient of interassay variation for Mn-SOD/
b-actin was 16.05%. The identity of the PCR product
from Mn-SOD cDNA amplification was verified by di-
gestion with Nva I and SacI. The first enzyme yielded the
predicted restriction fragments, while SacI did not digest
the amplified PCR product (no restriction site for this
endonuclease is present in the amplified region).
Fig. 1. Relationship between input of total RNA in the reaction and
cpm of the amplification band after reverse transcription-PCR of Mn-
SOD and b-actin gene products in PBMC and in the liver.
Fig. 2. (A) Relationship between the amount of Mn-SOD riboprobe
added to RNA extracted from normal PBMC and the ratio Mn-SOD
PCR product cpm/b-actin PCR product cpm. (B,C).The gel photo-
graphs show increasing intensity of the Mn-SOD amplification band
(B) but constant intensity of the b-actin amplification band (C), when
increasing amounts of a Mn-SOD riboprobe (0, 0.16, 0.31, 0.62, 1.25,
2.5, 5, 10, 20, and 40 pg, lines 2 to 11, respectively) were added to the
RNA extracted from normal PBMC. Line 1, molecular weight.
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Analysis of serum Mn-SOD levels
Serum Mn-SOD concentration was analyzed by
means of an ELISA kit (NOF corporation, Tokio, Japan)
using specific antihuman Mn-SOD antibodies. The assay
was performed following the instructions of the manu-
facturers. The sensitivity limit of the assay was 2.5
ng/ml.
Detection and quantification of HCV-RNA and HCV
genotyping
Serum HCV-RNA was studied by reverse transcrip-
tion-PCR as previously described.7 Two sets of primers
specific for the 59untranslated region of HCV genome
were used (59-CCTGTGAGGAACTACTGTCT-39 and
59-CTATCAGGCAGTACCACAAG-39 for outer prim-
ers; 59-ACTGTCTTCACGCAGAAAGC-39 and 59-
GACCCAACACTACTCGGCTA-39 for inner primers).
HCV-RNA was quantitated using a competitive PCR
technique as previously reported.7 HCV genotypes were
determined following the method of Viazov et al.23 as
described elsewhere.7,24 For genotype 4 the probe 59
G(A,G)CCGTCTTGGGGCC(A,C)AAATGAT was
used.
Statistical analysis
Results of Mn-SOD and TNFa are presented as
mean 6 standard deviation. Normality was assessed with
the Kolmogorov-Smirnov test. Statistical analysis of Mn-
SOD protein was performed using parametric tests
(Anova and Scheffe F-test). The statistical evaluation of
Mn-SOD and TNFa mRNA levels in PBMC and in the
liver was made using nonparametric tests (Kruskal–Wal-
lis and Mann–Whitney U-tests). The Wilcoxon signed-
rank test was used to compare the levels of Mn-SOD
mRNA before and after therapy in the same patients.
Associations between quantitative variables were studied
with Pearson‘s correlation coefficient. All p-values were
two tailed.
RESULTS
As shown in Fig. 3A, Mn-SOD mRNA levels in
PBMC were higher in patients with chronic HCV infec-
tion than in normal controls (1.14 6 0.69 vs. 0.50 6
0.25, p , .01). Patients who had cleared the virus and
normalized serum transaminases after IFN therapy
showed values of Mn-SOD mRNA in PBMC (0.76 6
0.23), that were significantly lower than subjects with
detectable viremia (p , .05) but still higher than healthy
controls (p , .01). However, Mn-SOD mRNA levels in
liver were similar in chronic hepatitis C and in normal
livers (1.28 6 0.82 vs. 0.84 6 0.38, p 5 .18, Fig. 3B).
The transcriptional expression of Mn-SOD in PBMC
was analyzed sequentially (before and after completion
IFN therapy) in 12 patients who exhibited complete
sustained response (both virological and biochemical) to
treatment. As shown in Fig. 4, the disappearence of
viremia was associated with a significant reduction in
Mn-SOD mRNA values.
Serum Mn-SOD levels were also higher in patients
with positive viremia than in normal controls (120.45 6
33.53 vs. 76.19 6 17.38, p , .001). Patients who had
eliminated HCV-RNA and normalized serum transami-
nases after IFN therapy showed serum Mn-SOD levels
similar to healthy controls (72.52 6 18.48 vs. 76.19 6
Fig. 3. Transcriptional expression of Mn-SOD gene (as ratio to that of b-actin) in PBMC (A) and in the liver (B) in healthy controls
(c), patients with detectable hepatitis C virus RNA in serum (HCV-RNA1) and patients who cleared hepatitis C virus RNA after IFN
therapy (HCV-RNA2). (In B, p 5 .18.)
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17.38, NS). In viremic patients we found a close rela-
tionship between the levels of serum Mn-SOD protein
and serum alanine aminotransferase (ALT) (r 5 .75, p ,
.001), probably reflecting the simultaneous release to
plasma of Mn-SOD protein and ALT from damaged liver
cells. No correlation was observed between Mn-SOD
protein in serum and Mn-SOD mRNA values in PBMC.
No relationship was observed between Mn-SOD
mRNA levels (in PBMC or in the liver) and serum
transaminases. Similarly, we did not find any correlation
between Mn-SOD mRNA values in the liver and the
Knodell’s score of the liver biopsy. When we analyzed
the relationship between Mn-SOD expression and treat-
ment outcome, we found no differences in pretreatment
Mn-SOD mRNA values between those patients who
subsequently showed sustained response to IFN and
those who subsequently failed to respond to the therapy
(1.16 6 0.77 vs. 1.12 6 0.66, p 5 .90).
We found no correlation between viral load and val-
ues of Mn-SOD mRNA in PBMC (r 5 .11, p 5 .53). We
also observed that the amount of Mn-SOD mRNA in
PBMC was similar in the different HCV genotypes.
Thus, Mn-SOD mRNA was 1.03 6 0.34, 1.19 6 0.78,
1.13 6 0.86, and 1.03 in HCV-RNA positive patients
with genotypes 1a (n 5 6), 1b (n 5 16), 3a (n 5 12), and
4 (n 5 1), respectively.
Because Mn-SOD expression is believed to be stim-
ulated by cytokines such as TNFa, which in turn causes
oxidative stress,8 we investigated the levels of TNFa
mRNA in PBMC and in the liver from patients and
controls where Mn-SOD mRNA had been previously
evaluated. As shown in Table 1, TNFa mRNA levels in
PBMC and in the liver were significantly elevated com-
pared with controls in HCV-RNA–positive subjects,
while the levels of TNFa mRNA in PBMC were within
normal range in patients who cleared HCV-RNA after
IFN therapy. Although the overall changes in the tran-
scriptional expression of TNFa paralleled those of Mn-
SOD, no significant correlation was found between these
two transcripts in PBMC or in the liver from patients
with chronic hepatitis C.
DISCUSSION
The pathogenetic mechanisms through which HCV
causes cell damage remain obscure, although it has been
suggested that oxidative stress may play a pathogenetic
role in this infection.2,3,25 Previous results from our own
group have shown that antioxidants such as N-acetyl-
cysteine, administered together with IFN, induced a sig-
nificant decrease in serum transaminases (although not
clearance of viremia) in patients previously resistant to
IFN alone.25
In this article we show that the transcriptional expres-
sion of Mn-SOD is increased in PBMC from patients
with chronic hepatitis C. In this disease, both PBMC and
the liver have been shown to be infected by HCV.1,26
The increase in Mn-SOD here reported appear to be
related to active viral infection because Mn-SOD was
found to significantly decrease in patients with sustained
virological and biochemical response following IFN
therapy. Because enhanced Mn-SOD expression appears
to be an adaptive response to increased oxidative
stress,15,16 our observations support the concept that dis-
turbed intracellular redox state may be implicated in the
pathogenesis of HCV infection. A significant elevation
of Mn-SOD protein was also found in serum from pa-
tients with chronic HCV infection. Mn-SOD protein did
not correlate with Mn-SOD mRNA values, but showed a
close correlation with ALT values, indicating that in-
creased serum levels of Mn-SOD may simply reflect
enzyme leakage from damaged hepatocytes and, thus,
the intensity of liver cell damage.
Increased oxidative stress has been demonstrated to
occur in other viral diseases, including human immuno-
deficiency virus type 1 infection.27,28 In this condition,
altered redox state has been adscribed to increased pro-
duction of proinflammatory cytokines such as TNFa.27
The relationship between ROS and TNFa is bidirectional
in that TNFa induces oxidative stress but also ROS
activate latent nuclear factor kB29 and increase TNFa
Fig. 4. Pre- and posttreatment values of Mn-SOD gene expression (as
a ratio to b-actin) in PBMC from patients with chronic hepatitis C who
showed sustained biochemical and virological response after interferon
treatment.
Table 1. Levels of TNFa mRNA (as a Ratio to b-Actin) in PBMC
and in the Liver
PBMC Liver
Healthy controls 0.18 6 0.11 0.86 6 0.26
Hepatitis C Virus-RNA (1) 0.39 6 0.31* 1.49 6 0.89*
Hepatitis C Virus-RNA (2) 0.12 6 0.06
* p , .05 vs healthy controls and Hepatitis C Virus-RNA (2).
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expression.30 In addition to increasing the production of
ROS, TNFa also induces the synthesis of Mn-SOD,31,32
and this latter effect can protect the cell against the
cytotoxic effects of TNFa.31,32 As shown in the present
report (which confirms our previous studies7), this cyto-
kine is overexpressed in PBMC and in the liver in
chronic hepatitis C. It thus seems possible that TNFa
might participate in causing oxidative stress and Mn-
SOD overexpression in PBMC in this condition.
We did not find any correlation between TNFa
mRNA and Mn-SOD mRNA levels in PBMC or between
the levels of the two transcripts in liver tissue. In fact,
despite the presence of increased TNFa mRNA values,
the levels of SOD message in the liver were not different
from controls. This absence of correlations does not
exclude the participation of TNFa in causing oxidative
stress in patients with hepatitis C. Although the induction
of Mn-SOD by TNFa occurs in most cells, there are
some human tumors cells lines and HIV-infected T lym-
phocytes where Mn-SOD is not induced by TNFa.31,33
On the other hand, it should be considered that Mn-SOD
expression is modulated by a diversity of cytokines and
proinflammatory mediators in addition to TNFa.
Among these cytokines, interleukin-1 (IL-1) and
IFN-g have been shown to increase Mn-SOD synthesis,
whereas transforming growth factor-b (TGF-b) mark-
edly inhibits the expression of this enzyme.34,35 Interest-
ingly TGF-b mRNA is considerably increased in the
liver of patients with chronic hepatitis C,36 while it is
normal in PBMC from these patients (E. Larrea, unpub-
lished data). This may contribute to explain why Mn-
SOD mRNA is high in PBMC but not overexpressed in
the liver in hepatitis C. If HCV infection causes similar
oxidative stress in the liver as in PBMC, the lack of
hepatic Mn-SOD induction in response to an altered
redox state might deprive the liver of an efficient protec-
tive mechanism against the noxious effects of
ROS,25,32,37 thus facilitating oxidative hepatocellular
damage in this virus infection.
In summary, this article shows that in HCV infection,
the adaptive response to oxygen free radicals, manifested
by the induction of Mn-SOD, was present in PBMC but
absent in the liver, suggesting that this organ may be less
protected against oxidative damage. The involvement of
oxidative stress in cell damage, viral persistance, and
resistance to IFN requires further study.
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ABBREVIATIONS
H2O2—hydrogen peroxide
HCV—hepatitis C virus
IFN—interferon
IL-1–interleukin-1
O2z2—superoxide ion
PBMC—peripheral blood mononuclear cells
ROS—reactive oxygen species
SOD—superoxide dismutase
TGF-b—transforming growth factor-b
TNFa—tumor necrosis factor-a
1241SOD and HCV infection
